A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD)
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs Pelacarsen (Primary)
- Indications Cardiovascular disorders; Hyperlipoproteinaemia; Myocardial infarction; Stroke
- Focus Registrational; Therapeutic Use
- Acronyms Lp(a)HORIZON
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 24 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 19 Aug 2022 Status changed from active, no longer recruiting to recruiting.
- 20 Jul 2022 According to Ionis Pharmaceuticals media release, topline data from the study are expected in 2025.